SCP Stock Overview
A biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Scope Fluidics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł170.80 |
| 52 Week High | zł239.00 |
| 52 Week Low | zł148.00 |
| Beta | -0.22 |
| 1 Month Change | 5.17% |
| 3 Month Change | -17.88% |
| 1 Year Change | -12.86% |
| 3 Year Change | 30.18% |
| 5 Year Change | 245.75% |
| Change since IPO | 838.46% |
Recent News & Updates
Shareholder Returns
| SCP | PL Medical Equipment | PL Market | |
|---|---|---|---|
| 7D | 2.9% | -0.002% | -1.7% |
| 1Y | -12.9% | -10.5% | 21.4% |
Return vs Industry: SCP underperformed the Polish Medical Equipment industry which returned -10.9% over the past year.
Return vs Market: SCP underperformed the Polish Market which returned 21.5% over the past year.
Price Volatility
| SCP volatility | |
|---|---|
| SCP Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 5.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PL Market | 9.2% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: SCP's share price has been volatile over the past 3 months.
Volatility Over Time: SCP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 30 | Piotr Garstecki | www.scopefluidics.com |
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.
Scope Fluidics S.A. Fundamentals Summary
| SCP fundamental statistics | |
|---|---|
| Market cap | zł465.59m |
| Earnings (TTM) | -zł18.78m |
| Revenue (TTM) | zł516.00k |
902.3x
P/S Ratio-24.8x
P/E RatioIs SCP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCP income statement (TTM) | |
|---|---|
| Revenue | zł516.00k |
| Cost of Revenue | zł29.12m |
| Gross Profit | -zł28.60m |
| Other Expenses | -zł9.81m |
| Earnings | -zł18.78m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | -6.89 |
| Gross Margin | -5,542.64% |
| Net Profit Margin | -3,640.50% |
| Debt/Equity Ratio | 0% |
How did SCP perform over the long term?
See historical performance and comparison